Invention Grant
US08981072B2 Nucleic acids encoding antibody polypeptides that antagonize CD40L
有权
编码拮抗CD40L的抗体多肽的核酸
- Patent Title: Nucleic acids encoding antibody polypeptides that antagonize CD40L
- Patent Title (中): 编码拮抗CD40L的抗体多肽的核酸
-
Application No.: US14101441Application Date: 2013-12-10
-
Publication No.: US08981072B2Publication Date: 2015-03-17
- Inventor: Steven G. Nadler , James K. Tamura , Laura Price , Robert P. Rehfuss , Suzanne J. Suchard , Anish Suri , James William Bryson , Aaron Yamniuk , Steven Grant , Olga Ignatovich , Philip Drew
- Applicant: Bristol-Myers Squibb Company , Domantis Limited
- Applicant Address: US NJ Princeton GB Brentford, Middlesex
- Assignee: Bristol-Myers Squibb Company,Domantis Limited
- Current Assignee: Bristol-Myers Squibb Company,Domantis Limited
- Current Assignee Address: US NJ Princeton GB Brentford, Middlesex
- Agency: Drinker Biddle & Reath LLP
- Main IPC: C12N15/13
- IPC: C12N15/13 ; C12N15/12 ; C12N5/10 ; C07K16/28 ; A61K39/395 ; A61K45/06 ; C07K16/46 ; A61K39/00 ; A61K38/00
Abstract:
Antibody polypeptides that specifically bind human CD40L are provided. The antibody polypeptides do not activate platelets. The antibody polypeptides are useful in the treatment of diseases involving CD40L activation, such as graft-related diseases and autoimmune diseases. The antibody polypeptides may be domain antibodies (dAbs) comprising a single VH or VK domain. The half-life of the antibody polypeptides may be increased by modifying the antibody polypeptides to be dual specific reagents that can also bind human serum albumin (HSA) or another antigen.
Public/Granted literature
- US20140099707A1 ANTIBODY POLYPEPTIDES THAT ANTAGONIZE CD40L Public/Granted day:2014-04-10
Information query
IPC分类:
